This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Clopidogrel

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Clopidogrel is an anti-platelet drug, of the thienopyridine class, which is licensed for the secondary prophylaxis of atherosclerotic complications in patients with:

  • ischaemic heart disease
  • cerebrovascular disease
  • peripheral vascular disease

The dose is 75 mg per day.

The principal side-effect is haemorrhage, including:

  • gastrointestinal
  • intracranial

There may be gastrointestinal upset.

Maximal inhibition of platelet aggregation is achieved after 4-7 days with clopidogrel 75 mg per day (1).

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  1. Solet D et al. The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease. Am J Med 2001;111:45-53.
  2. Drug and Therapeutics Bulletin 1999; 37 (8): 59-61.
  3. Factfile 12/98. Antithrombotic drugs. British Heart Foundation.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.